Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 258

1.

Emergency coronary artery bypass grafting in patients with acute myocardial infarction treated with glycoprotein IIb/IIIa receptor inhibitors.

De Carlo M, Maselli D, Cortese B, Ciabatti N, Gistri R, Levantino M, Balbarini A, De Caterina R, Petronio AS.

Int J Cardiol. 2008 Jan 24;123(3):229-33. Epub 2007 Apr 11. Review.

PMID:
17433463
[PubMed - indexed for MEDLINE]
2.

Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.

Dyke CM.

Am Heart J. 1999 Oct;138(4 Pt 2):307-16. Review.

PMID:
10502236
[PubMed - indexed for MEDLINE]
3.

Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial.

Zeymer U, Margenet A, Haude M, Bode C, Lablanche JM, Heuer H, Schröder R, Kropff S, Bourkaib R, Banik N, Zahn R, Teiger E.

J Am Coll Cardiol. 2010 Aug 3;56(6):463-9. doi: 10.1016/j.jacc.2009.08.093.

PMID:
20670755
[PubMed - indexed for MEDLINE]
Free Article
4.

Emergency coronary artery bypass surgery in the era of glycoprotein IIb/IIIa receptor antagonist use.

Pang JT, Fort S, Della Siega A, Cohen EA.

J Card Surg. 2002 Sep-Oct;17(5):425-31.

PMID:
12630543
[PubMed - indexed for MEDLINE]
5.

Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.

Bhatt DL, Topol EJ.

JAMA. 2000 Sep 27;284(12):1549-58. Review.

PMID:
11000650
[PubMed - indexed for MEDLINE]
6.

An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.

Adgey AA.

Am Heart J. 1998 Apr;135(4):S43-55. Review.

PMID:
9539495
[PubMed - indexed for MEDLINE]
7.

Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials.

De Luca G, Navarese E, Marino P.

Eur Heart J. 2009 Nov;30(22):2705-13. doi: 10.1093/eurheartj/ehp118. Epub 2009 Oct 28. Review.

PMID:
19875386
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Platelet inhibition and GP IIb/IIIa receptor occupancy by intracoronary versus intravenous bolus administration of abciximab in patients with ST-elevation myocardial infarction.

Desch S, Siegemund A, Scholz U, Adam N, Eitel I, de Waha S, Fürnau G, Lurz P, Wetzel S, Schuler G, Thiele H.

Clin Res Cardiol. 2012 Feb;101(2):117-24. doi: 10.1007/s00392-011-0372-6. Epub 2011 Oct 21.

PMID:
22015616
[PubMed - indexed for MEDLINE]
9.

[Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].

Auer J, Berent R, Lassnig E, Weber T, Maurer E, Eber B.

Herz. 2003 Aug;28(5):393-403. Review. German.

PMID:
12928738
[PubMed - indexed for MEDLINE]
10.

Platelet glycoprotein IIb/IIIa inhibitor use during percutaneous coronary intervention: IIb or Not IIb, what is the question?

Young JJ, Kereiakes DJ.

J Invasive Cardiol. 2002 Jul;14(7):404-10. Review.

PMID:
12082194
[PubMed - indexed for MEDLINE]
11.

Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials.

Tricoci P, Newby LK, Hasselblad V, Kong DF, Giugliano RP, White HD, Théroux P, Stone GW, Moliterno DJ, Van de Werf F, Armstrong PW, Prabhakaran D, Rasoul S, Bolognese L, Durand E, Braunwald E, Califf RM, Harrington RA.

Circ Cardiovasc Qual Outcomes. 2011 Jul;4(4):448-58. doi: 10.1161/CIRCOUTCOMES.110.960294. Epub 2011 Jun 28. Review.

PMID:
21712522
[PubMed - indexed for MEDLINE]
Free Article
12.

Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry).

Akerblom A, James SK, Koutouzis M, Lagerqvist B, Stenestrand U, Svennblad B, Oldgren J.

J Am Coll Cardiol. 2010 Aug 3;56(6):470-5. doi: 10.1016/j.jacc.2009.10.093.

PMID:
20670756
[PubMed - indexed for MEDLINE]
Free Article
13.

Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.

Ferguson JJ, Antman EM, Bates ER, Cohen M, Every NR, Harrington RA, Pepine CJ, Theroux P; NICE-3 Investigators.

Am Heart J. 2003 Oct;146(4):628-34.

PMID:
14564315
[PubMed - indexed for MEDLINE]
14.

Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.

Lincoff AM, Tcheng JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, Kleiman NS, Booth JE, Balog C, Cabot CF, Anderson KM, Weisman HF, Topol EJ.

Circulation. 1999 Apr 20;99(15):1951-8.

PMID:
10208997
[PubMed - indexed for MEDLINE]
Free Article
15.

Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction.

Ernst NM, Suryapranata H, Miedema K, Slingerland RJ, Ottervanger JP, Hoorntje JC, Gosselink AT, Dambrink JH, de Boer MJ, Zijlstra F, van 't Hof AW.

J Am Coll Cardiol. 2004 Sep 15;44(6):1187-93.

PMID:
15364318
[PubMed - indexed for MEDLINE]
Free Article
16.
17.

Short-term comparative outcomes associated with the use of GP IIb/IIIa antagonists in patients undergoing coronary intervention.

Kimmelstiel C, Phang R, Rehman A, Rand W, Miele R, Rhofiry J, MacIsaac DA, Gouveia W, Denier D, Becker RC.

J Thromb Thrombolysis. 2001 May;11(3):203-9.

PMID:
11577258
[PubMed - indexed for MEDLINE]
18.

A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.

Gurm HS, Tamhane U, Meier P, Grossman PM, Chetcuti S, Bates ER.

Circ Cardiovasc Interv. 2009 Jun;2(3):230-6. doi: 10.1161/CIRCINTERVENTIONS.108.847996. Epub 2009 Apr 21.

PMID:
20031720
[PubMed - indexed for MEDLINE]
Free Article
19.

Comparison of abciximab versus eptifibatide during percutaneous coronary intervention in ST-segment elevation myocardial infarction (from the HORIZONS-AMI trial).

Singh HS, Dangas GD, Guagliumi G, Yu J, Witzenbichler B, Kornowski R, Grines C, Gersh B, Dudek D, Mehran R, Stone GW.

Am J Cardiol. 2012 Oct 1;110(7):940-7. doi: 10.1016/j.amjcard.2012.05.026. Epub 2012 Jun 28.

PMID:
22748356
[PubMed - indexed for MEDLINE]
20.

Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis.

Montalescot G, Borentain M, Payot L, Collet JP, Thomas D.

JAMA. 2004 Jul 21;292(3):362-6.

PMID:
15265852
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk